for DNMT3B; 5'-AACTTTCAGAAGGGCCAGGT-3' (forward) and 5'-GTAGACAGGGGCGAAGACTG-3' (reverse) for HMOX1; 5'-CAGCTCACCGAGAGC CTAGT-3' (forward) and 5'-GCCTCCTTCATGGCA TAGTT-3' (reverse) for NQO1; and 5'-AGCC CAGCACATCCAGTCA-3' (forward) and 5'-TGTGGG CAACCTGGGAGTAG-3' (reverse) for Nrf2; and 5'-AGGCCAACCGCGAGAAG-3' and 5'-ACAGCCTGG ATAGCAACGTACA-3' for β-actin.
siRNAs
Predesigned siRNAs targeting DNMT3B (Cat. No. SI00092967 and SI04987157) and Nrf2 (SI03246614) were purchased from Qiagen (Valencia, CA, USA). Figure S1 : The quinone-containing compound nanaomycin and the BET bromodomain inhibitor JQ1 do not exert considerable cytotoxicity against normal embryonic fibroblasts, but synergistically reduce the number of c-Myc over-expressing cancer cells. A-C. WI38 embryonic fibroblasts, c-Myc over-expressing PSN1 pancreatic, COLO320 and HCT116 colon cancer cells were treated with vehicle control, JQ1, nanaomycin, or JQ1 plus nanaomycin at the indicated doses for 72 hours, followed by Alamar Blue assays. Relative numbers of cells were expressed as a percentage compared with samples treated with vehicle control. All experiments were repeated for at least three times. Error bars represent standard error. C. CI values were determined for a mutually exclusive interaction using the Calcusyn program; a CI of <1, 1, or >1 indicates synergistic, additive and antagonistic effects respectively. CI 75 and CI 90 represented CIs for 75 and 90% reduction in the number of viable cells respectively. r a is the linear correlation coefficient of the median-effect plot. siRNA, N-Myc siRNA-1 or N-Myc siRNA-2. Twenty-four hours later, cells were treated with vehicle control or a range of doses of nanaomycin for 72 hours. The numbers of viable cells were examined by Alamar blue assays. B. BE(2)-C and Kelly cells were transfected with control siRNA, DNMT3B siRNA-1 or DNMT3B siRNA-2, followed by RT-PCR analysis of DNMT3B mRNA expression 48 hours after siRNA transfection. C. BE(2)-C and Kelly cells were transfected with control siRNA, DNMT3B siRNA-1 or DNMT3B siRNA-2 for 24 hours, then treated with control or JQ1 at the indicated doses for another 72 hour followed by Alamar blue assays. D-E. BE(2)-C and Kelly cells were treated with a range of doses of JQ1 and/or a range of doses of the DNMT inhibitor 5-aza-2-deoxycytidine or 5-azacytidine for 72 hours. The numbers of viable cells were examined by Alamar blue assays 72 hours later. E. CI values were determined for a mutually exclusive interaction using the Calcusyn program; a CI of <1, 1, or >1 indicates synergistic, additive and antagonistic effects respectively. CI 75 and CI 90 represented CIs for 75 and 90% reduction in the number of viable cells respectively. r a is the linear correlation coefficient of the median-effect plot.
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